Immunomodulatory Therapy for the Management of Loiasis

Christina Coyle¹, Louis M Weiss^{1

2}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New, York, USA.
² Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA.

Editorial

Christina Coyle et al. Clin Infect Dis. 2021.

. 2021 Oct 5;73(7):e1632-e1633.

doi: 10.1093/cid/ciaa1367.

Christina Coyle¹, Louis M Weiss^{1

2}

¹ Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New, York, USA.
² Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA.

No abstract available

Keywords: IgE; IL-5; adverse reactions; diethylcarbamazine (DEC); immune modulation; loiasis; reslizumab; therapy.

Comment on

A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.
Legrand F, Herrick J, Makiya M, Ramanathan R, Thompson R, Rampertaap S, Stoddard J, Ware J, Fay MP, Holland-Thomas N, Nutman TB, Klion AD. Legrand F, et al. Clin Infect Dis. 2021 Oct 5;73(7):e1624-e1631. doi: 10.1093/cid/ciaa1365. Clin Infect Dis. 2021. PMID: 32910141 Free PMC article. Clinical Trial.